Long COVID and ME/CFS often start the same way: after an infection. The symptoms overlap too. Crushing fatigue. Brain fog. Pain. Sleep that never feels refreshing.
Doctors have struggled to tell them apart. Standard blood tests rarely show anything unusual. That leaves patients feeling dismissed, and researchers stuck on how to help.
The problem is big. Long COVID alone affects an estimated 65 million people worldwide. ME/CFS affects millions more. Yet there are no approved treatments for either.
The surprising shift
For a long time, many researchers assumed these two conditions might be the same illness wearing different names. The thinking was simple: similar triggers, similar symptoms, probably similar biology.
But here's the twist. When scientists looked deeply at the immune system, the two illnesses did not match at all. In fact, they almost looked like opposites.
What your immune cells are really doing
Your immune system works a bit like airport security. Some cells are scanners. Some are guards. Some hand out ID badges so the right cells know where to go.
In long COVID, that airport looked overworked. Scanners were flashing. Guards were waving everyone through. But many had been on shift too long and were burning out. Scientists call this "immune activation with exhaustion."
In ME/CFS, the same airport looked quiet in a worrying way. Important ID badges were missing. Security cells could not find their gates. The system seemed tired, confused, and slow to respond.
Same building. Very different problems.
Researchers looked at blood samples from 207 people. That included 103 with ME/CFS, 63 with long COVID, and 41 healthy controls.
They used a tool called flow cytometry. It sorts immune cells by type and checks what each one is doing. They focused on monocytes, dendritic cells, and T cells, the "frontline" of the immune response.
Long COVID patients showed signs of ongoing immune activity. Certain monocytes shifted into a repair-focused "M2" mode. A protein called CD80, which helps cells talk to each other, was turned up. Dendritic cells, the messengers of the immune system, were more numerous.
But those same cells showed signs of exhaustion. It was as if the immune system was stuck in "on" mode for so long that it started to wear out.
ME/CFS looked different. Key communication signals were turned down. A traffic-control protein called CCR7, which helps immune cells travel to the right spots, was not working well. The overall activity looked less coordinated, almost sleepy.
This doesn't mean we now have a blood test or treatment for either condition.
This is where things get interesting
When researchers used statistical tools to map these patterns, long COVID looked like a busy web of connected immune activity. ME/CFS looked more scattered and disconnected.
That tells a powerful story. These may be two different illnesses with two different engines driving them, even if the symptoms feel the same to the person living with them.
Where this fits in the bigger picture
Scientists have been searching for biological markers, or biomarkers, that prove these conditions are "real" and measurable. Patients have long said they were.
This study adds strong support. It also suggests that treatments will likely need to be different for each group. A drug that calms an overactive immune system might help long COVID but could make ME/CFS worse. And vice versa.
If you or someone you love has long COVID or ME/CFS, this research will not change your care today. No new test is available. No new medicine has been approved.
But it is a meaningful step. It may help future doctors tell the two conditions apart. It may guide drug companies toward treatments that actually match the problem.
For now, keep working with a doctor who takes your symptoms seriously. Pacing, sleep support, and managing other health issues remain the main tools.
The honest limitations
This was a single study with about 200 people. That is a reasonable size, but not huge. The work was posted on medRxiv, meaning it has not yet gone through full peer review.
The researchers also looked at a single moment in time. They did not follow patients for months or years. So we do not yet know if these immune patterns change as people get better, worse, or stay the same.
The next step is confirming these findings in larger, more diverse groups of patients. Researchers will also want to see if these immune patterns shift with treatment or time.
If the signatures hold up, they could become the basis for the first real diagnostic tests. They could also guide clinical trials toward treatments aimed at the right target, calming an overactive immune system in long COVID, or waking up a sluggish one in ME/CFS.
Science moves slowly. But for patients who have felt invisible for years, studies like this one offer something rare and valuable: proof that what they feel is rooted in real, measurable biology.